Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs

Mutagenesis

Volumn 26, Issue 3, 2011, Pages 359-369

  Villarini, Milena ^a   Dominici, Luca ^a   Piccinini, Renza ^a   Fatigoni, Cristina ^a   Ambrogi, Maura ^a   Curti, Gianluca ^a   Morucci, Piero ^a   Muzi, Giacomo ^a   Monarca, Silvano ^a   Moretti, Massimo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PROTEIN P53; RALTITREXED; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA POLYMORPHISM; DRUG CARCINOGENICITY; EXCISION REPAIR; FEMALE; GENETIC VARIABILITY; GENOTOXICITY; GENOTYPE; GLOVE; HOSPITAL PERSONNEL; HUMAN; HUMAN CELL; ITALY; LEUKOCYTE; MALE; MASK; MATERIALS HANDLING; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OXIDATIVE STRESS; PRIORITY JOURNAL; URINARY EXCRETION; WORK ENVIRONMENT;

ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; COMET ASSAY; CYTARABINE; DNA DAMAGE; FLUOROURACIL; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ITALY; NURSING STAFF, HOSPITAL; OCCUPATIONAL EXPOSURE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955411778     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/geq102     Document Type: Article

References (100)

1. Black, D. J. and Livingston, R. B. (1990) Antineoplastic drugs in 1990. A review (Part II). Drugs, 39, 652-673.
2. Black, D. J. and Livingston, R. B. (1990) Antineoplastic drugs in 1990. A review (Part I). Drugs, 39, 489-501.
3. Salmon, S. and Apple, M. (1979) Chemotherapeutic agents: cancer chemotherapy. In Harper, H. A., Rodwel, V. W. and Mayes, P. A. (eds), Physiological Chemistry. Los Altos, CA, USA. pp. 471-503.
4. Erlichman, C. and Moore, M. (eds.) (1996) Carcinogenesis: A Late Complication of Cancer Chemotherapy. Lippincott-Raven, Philadelphia, PA, USA.
5. Connor, T. H. and McDiarmid, M. A. (2006) Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J. Clin., 56, 354-365. (Pubitemid 44903909)
6. IARC (1975) Some Aziridines, N-, S- and O-Mustards and Selenium. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Vol. 9, International Agency for Research on Cancer, Lyon France.
7. IARC (1976) Some Naturally Occurring Substances. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Vol. 10, International Agency for Research on Cancer, Lyon, France.
8. IARC (1978) Some N-Nitroso Compounds. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Vol. 17, International Agency for Research on Cancer, Lyon, France.
9. IARC (1987) Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans; Vol. Supplement No. 7, International Agency for Research on Cancer, Lyon, France.
10. IARC (1990) Pharmaceutical Drugs. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Vol. 50, International Agency for Research on Cancer, Lyon, France.
11. IARC (1996) Some Pharmaceutical Drugs. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans; Vol. 66, International Agency for Research on Cancer, Lyon, France.
12. IARC (2000) Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Vol. 76, International Agency for Research on Cancer, Lyon, France.
13. Skov, T., Lynge, E., Maarup, B., Olsen, J., Rorth, M. and Winthereik, H. (1990) Risks for physicians handling antineoplastic drugs. Lancet, 336, 1446.
14. Skov, T., Maarup, B., Olsen, J., Rorth, M., Winthereik, H. and Lynge, E. (1992) Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br. J. Ind. Med., 49, 855-861.
15. Falck, K., Grohn, P., Sorsa, M., Vainio, H., Heinonen, E. and Holsti, L. R. (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet, 1, 1250-1251.
16. Anderson,R.W., Puckett, W.H., Jr.,Dana, W. J.,Nguyen, T. V., Theiss, J. C. and Matney, T. S. (1982) Risk of handling injectable antineoplastic agents. American Journal of Hospital Pharmacy, 39, 1881-1887. (Pubitemid 12002311)
17. Burgaz, S., Bayhan, A. and Karakaya, A. E. (1988) Thioether excretion of workers exposed to bitumen fumes. Int. Arch. Occup. Environ. Health, 60, 347-349.
18. Pyy, L., Sorsa, M. and Hakala, E. (1988) Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am. Ind. Hyg. Assoc. J., 49, 314-317.
19. McDevitt, J. J., Lees, P. S. and McDiarmid, M. A. (1993) Exposure of hospital pharmacists and nurses to antineoplastic agents. J. Occup. Med., 35, 57-60. (Pubitemid 23018112)
20. Sessink, P. J., Cerna, M., Rossner, P., Pastorkova, A., Bavarova, H., Frankova, K., Anzion, R. B. and Bos, R. P. (1994) Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat. Res., 309, 193-199. (Pubitemid 24268428)
21. Sessink, P. J., Friemel, N. S., Anzion, R. B. and Bos, R. P. (1994) Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int. Arch. Occup. Environ. Health, 65, 401-403. (Pubitemid 24228373)
22. Sessink, P. J., Timmersmans, J. L., Anzion, R. B. and Bos, R. P. (1994) Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of alpha-fluoro-beta-alanine in urine. J. Occup. Med., 36, 79-83. (Pubitemid 24020694)
23. Sessink, P. J., Van de Kerkhof, M. C., Anzion, R. B., Noordhoek, J. and Bos, R. P. (1994) Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch. Environ. Health, 49, 165-169. (Pubitemid 24153799)
24. Baker, E. S. and Connor, T. H. (1996) Monitoring occupational exposure to cancer chemotherapy drugs. Am. J. Health Syst. Pharm., 53, 2713-2723. (Pubitemid 26386655)
25. Sorsa, M. and Anderson, D. (1996) Monitoring of occupational exposure to cytostatic anticancer agents. Mutat. Res., 355, 253-261. (Pubitemid 26275513)
26. Sessink, P. J. and Bos, R. P. (1999) Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf., 20, 347-359. (Pubitemid 29196911)
27. Turci, R., Sottani, C., Spagnoli, G. and Minoia, C. (2003) Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 789, 169-209. (Pubitemid 36549189)
28. Laffon, B., Teixeira, J. P., Silva, S., Loureiro, J., Torres, J., Pasaro, E., Mendez, J. and Mayan, O. (2005) Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am. J. Ind. Med., 48, 128-136. (Pubitemid 41134215)
29. Rekhadevi, P. V., Sailaja, N., Chandrasekhar, M., Mahboob, M., Rahman, M. F. and Grover, P. (2007) Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis, 22, 395-401. (Pubitemid 350098495)
30. Testa, A., Giachelia, M., Palma, S., Appolloni, M., Padua, L., Tranfo, G., Spagnoli, M., Tirindelli, D. and Cozzi, R. (2007) Occupational exposure to antineoplastic agents induces a high level of chromosome damage. Lack of an effect of GST polymorphisms. Toxicol. Appl. Pharmacol., 223, 46-55. (Pubitemid 47224967)
31. Cornetta, T., Padua, L., Testa, A., Ievoli, E., Festa, F., Tranfo, G., Baccelliere, L. and Cozzi, R. (2008) Molecular biomonitoring of a population of nurses handling antineoplastic drugs. Mutat. Res., 638, 75-82.
32. Mader, R. M., Kokalj, A., Kratochvil, E., Pilger, A. and Rudiger, H. W. (2008) Longitudinal biomonitoring of nurses handling antineoplastic drugs. J. Clin. Nurs., 18, 263-269.
33. Kopjar, N., Garaj-Vrhovac, V., Kasuba, V., Rozgaj, R., Ramic, S., Pavlica, V. and Zeljezic, D. (2009) Assessment of genotoxic risks in Croatian health care workers occupationally exposed to cytotoxic drugs: a multi-biomarker approach. Int. J. Hyg. Environ. Health, 212, 414-431.
34. Kopjar, N., Kasuba, V., Rozgaj, R., Zeljezic, D., Milic, M., Ramic, S., Pavlica, V. and Milkovic-Kraus, S. (2009) The genotoxic risk in health care workers occupationally exposed to cytotoxic drugs-a comprehensive evaluation by the SCE assay. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng., 44, 462-479.
35. Rombaldi, F., Cassini, C., Salvador, M., Saffi, J. and Erdtmann, B. (2009) Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. Mutagenesis, 24, 143-148.
36. Singh, N. P., McCoy, M. T., Tice, R. R. and Schneider, E. L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res., 175, 184-191.
37. Tice, R. R., Agurell, E., Anderson, D. et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen., 35, 206-221. (Pubitemid 30196665)
38. Fuchs, J., Hengstler, J. G., Jung, D., Hiltl, G., Konietzko, J. and Oesch, F. (1995) DNA damage in nurses handling antineoplastic agents. Mutat. Res., 342, 17-23.
39. Undeger, U., Basaran, N., Kars, A. and Guc, D. (1999) Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat. Res., 439, 277-285. (Pubitemid 29094820)
40. Maluf, S. W. and Erdtmann, B. (2000) Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat. Res., 471, 21-27.
41. Kopjar, N. and Garaj-Vrhovac, V. (2001) Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical personnel handling antineoplastic drugs. Mutagenesis, 16, 71-78. (Pubitemid 32050829)
42. Deng, H., Zhang, M., He, J., Wu, W., Jin, L., Zheng, W., Lou, J. and Wang, B. (2005) Investigating genetic damage in workers occupationally exposed to methotrexate using three genetic end-points. Mutagenesis, 20, 351-357. (Pubitemid 41219864)
43. Hongping, D., Jianlin, L., Meibian, Z., Wei, W., Lifen, J., Shijie, C., Wei, Z., Baohong, W. and Jiliang, H. (2006) Detecting the cytogenetic effects in workers occupationally exposed to vincristine with four genetic tests. Mutat. Res., 599, 152-159. (Pubitemid 44043168)
44. Ursini, C. L., Cavallo, D., Colombi, A., Giglio, M., Marinaccio, A. and Iavicoli, S. (2006) Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Int. Arch. Occup. Environ. Health, 80, 134-140. (Pubitemid 44644634)
45. Yoshida, J., Kosaka, H., Tomioka, K. and Kumagai, S. (2006) Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J. Occup. Health, 48, 517-522. (Pubitemid 46057884)
46. Sasaki, M., Dakeishi, M., Hoshi, S., Ishii, N. and Murata, K. (2008) Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay. J. Occup. Health, 50, 7-12. (Pubitemid 351680002)
47. Cavallo, D., Ursini, C. L., Rondinone, B. and Iavicoli, S. (2009) Evaluation of a suitable DNA damage biomarker for human biomonitoring of exposed workers. Environ. Mol. Mutagen., 50, 781-790.
48. Doetsch, P. W., Henner, W. D., Cunningham, R. P., Toney, J. H. and Helland, D. E. (1987) A highly conserved endonuclease activity present in Escherichia coli, bovine, and human cells recognizes oxidative DNA damage at sites of pyrimidines. Mol. Cell. Biol., 7, 26-32. (Pubitemid 17230381)
49. Boiteux, S., Gajewski, E., Laval, J. and Dizdaroglu, M. (1992) Substrate specificity of the Escherichia coli Fpg protein (formamidopyrimidine- DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry, 31, 106-110.
50. Collins, A. R., Duthie, S. J. and Dobson, V. L. (1993) Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis, 14, 1733-1735. (Pubitemid 23290881)
51. Graham, F. L. and Whitmore, G. F. (1970) Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5#- triphosphate. Cancer Res., 30, 2636-2644.
52. Spriggs, D., Robbins, G., Ohno, Y. and Kufe, D. (1987) Detection of 1- beta-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res., 47, 6532-6536. (Pubitemid 18019650)
53. Gedik, C. M. and Collins, A. R. (1991) The mode of action of 1-beta-Darabinofuranosylcytosine in inhibiting DNA repair; new evidence using a sensitive assay for repair DNA synthesis and ligation in permeable cells. Mutat. Res., 254, 231-237.
54. Martin, F. L., Cole, K. J., Orme, M. H., Grover, P. L., Phillips, D. H. and Venitt, S. (1999) The DNA repair inhibitors hydroxyurea and cytosine arabinoside enhance the sensitivity of the alkaline single-cell gel electrophoresis ('comet') assay in metabolically-competent MCL-5 cells. Mutat. Res., 445, 21-43. (Pubitemid 29474932)
55. Norppa, H. (2004) Cytogenetic biomarkers and genetic polymorphisms. Toxicol. Lett., 149, 309-334. (Pubitemid 38469850)
56. Pavanello, S. and Clonfero, E. (2000) Biological indicators of genotoxic risk and metabolic polymorphisms. Mutat. Res., 463, 285-308.
57. Ingelman-Sundberg, M. (2001) Genetic variability in susceptibility and response to toxicants. Toxicol. Lett., 120, 259-268. (Pubitemid 32375092)
58. Schoket, B., Papp, G., Levay, K., Mrackova, G., Kadlubar, F. F. and Vincze, I. (2001) Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutat. Res., 482, 57-69. (Pubitemid 32787082)
59. Ginsberg,G., Smolenski, S.,Neafsey, P.,Hattis,D.,Walker,K., Guyton,K. Z., Johns,D.O. andSonawane,B. (2009)The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes. J. Toxicol. Environ. Health B Crit. Rev., 12, 307-333.
60. Robles, A. I., Linke, S. P. and Harris, C. C. (2002) The p53 network in lung carcinogenesis. Oncogene, 21, 6898-6907. (Pubitemid 35221936)
61. Wu, X., Zhao, H., Amos, C. I., Shete, S., Makan, N., Hong, W. K., Kadlubar, F. F. and Spitz, M. R. (2002) p.53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst., 94, 681-690. (Pubitemid 34552489)
62. Koushik, A., Platt, R. W. and Franco, E. L. (2004) p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol. Biomarkers Prev., 13, 11-22. (Pubitemid 38116615)
63. Micoli, G., Turci, R., Arpellini, M. and Minoia, C. (2001) Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 750, 25-32. (Pubitemid 33648326)
64. Sannolo, N., Miraglia, N., Biglietto, M., Acampora, A. and Malorni, A. (1999) Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry. J. Mass Spectrom., 34, 845-849.
65. Moretti, M., Dell'Omo, M., Villarini, M., Pastorelli, R., Muzi, G., Airoldi, L. and Pasquini, R. (2007) Primary DNA damage and genetic polymorphisms for CYP1A1, EPHX and GSTM1 in workers at a graphite electrode manufacturing plant. BMC Public Health, 7, 270.
66. Villarini, M., Moretti, M., Fatigoni, C., Agea, E., Dominici, L., Mattioli, A., Volpi, R. and Pasquini, R. (2008) Evaluation of primary DNA damage, cytogenetic biomarkers and genetic polymorphisms for CYP1A1 and GSTM1 in road tunnel construction workers. J. Toxicol. Environmental Health, 71, 1430-1439.
67. Andreoli, C., Leopardi, P., Rossi, S. and Crebelli, R. (1999) Processing of DNA damage induced by hydrogen peroxide and methyl methanesulfonate in human lymphocytes: analysis by alkaline single cell gel electrophoresis and cytogenetic methods. Mutagenesis, 14, 497-504.
68. Rahman, S. H., Nanny, C., Ibrahim, K., O'Reilly, D., Larvin, M., Kingsnorth, A. J. and McMahon, M. J. (2005) Genetic polymorphisms of GSTT1, GSTM1, GSTP1, MnSOD, and catalase in nonhereditary chronic pancreatitis: evidence of xenobiotic stress and impaired antioxidant capacity. Dig. Dis. Sci., 50, 1376-1383. (Pubitemid 41184772)
69. Omori, S., Yoshida, S., Kennedy, S. H., Negoro, K., Hamana, S., Barlow, D. H. and Maruo, T. (2004) Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. J. Soc. Gynecol. Investig., 11, 232-236. (Pubitemid 38561368)
70. Lovell, D. P. and Omori, T. (2008) Statistical issues in the use of the comet assay. Mutagenesis, 23, 171-182.
71. Duez, P., Dehon, G., Kumps, A. and Dubois, J. (2003) Statistics of the Comet assay: a key to discriminate between genotoxic effects. Mutagenesis, 18, 159-166. (Pubitemid 36336533)
72. Wiklund, S. J. and Agurell, E. (2003) Aspects of design and statistical analysis in the Comet assay. Mutagenesis, 18, 167-175. (Pubitemid 36336534)
73. Tice, R. R., Strauss, G. H. and Peters, W. P. (1992) High-dose combination alkylating agents with autologous bone-marrow support in patients with breast cancer: preliminary assessment of DNA damage in individual peripheral blood lymphocytes using the single cell gel electrophoresis assay. Mutat. Res., 271, 101-113.
74. Causon, R. (1997) Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J. Chromatogr. B Biomed. Sci. Appl., 689, 175-180. (Pubitemid 27089650)
75. GURI (1999) Provvedimento di Linee-Guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario (Repertorio Atti No. 736). Gazzetta Ufficiale della Repubblica Italiana (Offcial Gazette of the Italian Republic), 07 October 1999, No. 236, Rome, Italy.
76. NIH (1983) Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication 83-2621, Bethesda, MD, USA: National Institutes of Health.
77. AMA (1985) Guidelines for handling parenteral antineoplastics. Council on Scientific Affairs (American Medical Association). JAMA, 253, 1590-1592.
78. OSHA (1986) OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am. J. Hosp. Pharm., 43, 1193-1204.
79. ASHP (1990) ASHP (American Society of Hospital Pharmacists) technical assistance bulletin on handling cytotoxic and hazardous drugs. Am. J. Hosp. Pharm, 47, 1033-1049.
80. OSHA (1996) Controlling occupational exposure to hazardous drugs. Occupational Safety and Health Administration. Am. J. Health Syst. Pharm., 53, 1669-1685.
81. OSHA (2000) OSHA Technical Manual. Hospital Investigations: Health Hazard-Section VI. Occupational Safety and Health Administration, US Department of Labor, Washington, DC, USA.
82. HSE (2003) Safe Handling of Cytotoxic Drugs, Information Sheet MISC 615. Health and Safety Executive, Suffolk, UK.
83. NIOSH (2004) NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Department of Health and Human Services, Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health, Washington, DC, USA.
84. ASHP (2006) ASHP (American Society of Hospital Pharmacists) guidelines on handling hazardous drugs. Am. J. Hosp. Pharm., 63, 1172-1193.
85. Moller, P., Knudsen, L. E., Loft, S. and Wallin, H. (2000) The comet assay as a rapid test in biomonitoring occupational exposure to DNAdamaging agents and effect of confounding factors. Cancer Epidemiol. Biomarkers Prev., 9, 1005-1015.
86. Dabholkar, M., Bradshaw, L., Parker, R. J., Gill, I., Bostick-Bruton, F., Muggia, F. M. and Reed, E. (1992) Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ. Health Perspect., 98, 53-59. (Pubitemid 23061782)
87. Anderson, D., Dhawan, A., Yu, T. W. and Plewa, M. J. (1996) An investigation of bone marrow and testicular cells in vivo using the comet assay. Mutat. Res., 370, 159-174. (Pubitemid 26365154)
88. Olive, P. L. and Banath, J. P. (1995) Sizing highly fragmented DNA in individual apoptotic cells using the comet assay and a DNA crosslinking agent. Exp. Cell Res., 221, 19-26.
89. Wojewodzka, M., Kruszewski, M., Iwanenko, T., Collins, A. R. and Szumiel, I. (1999) Lack of adverse effect of smoking habit on DNA strand breakage and base damage, as revealed by the alkaline comet assay. Mutat. Res., 440, 19-25. (Pubitemid 29129523)
90. Ziegler, E., Mason, H. J. and Baxter, P. J. (2002) Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup. Environ. Med., 59, 608-612. (Pubitemid 34983587)
91. Schreiber, C., Radon, K., Pethran, A., Schierl, R., Hauff, K., Grimm, C. H., Boos, K. S. and Nowak, D. (2003) Uptake of antineoplastic agents in pharmacy personnel. Part II: study of work-related risk factors. Int. Arch. Occup. Environ. Health, 76, 11-16. (Pubitemid 36740715)
92. Mason, H. J., Blair, S., Sams, C., Jones, K., Garfitt, S. J., Cuschieri, M. J. and Baxter, P. J. (2005) Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann. Occup. Hyg., 49, 603-610. (Pubitemid 41442685)
93. Turci, R. and Minoia, C. (2006) Residual hazard assessment related to handling of antineoplastic drugs: safety system evolution and quality assurance of analytical measurement. Ann. N. Y. Acad. Sci., 1076, 649-656. (Pubitemid 44955296)
94. Touzin, K., Bussieres, J. F., Langlois, E., Lefebvre, M. and Gallant, C. (2008) Cyclophosphamide contamination observed on the external surfaces of drug vials and the efficacy of cleaning on vial contamination. Ann. Occup. Hyg., 52, 765-771.
95. Touzin, K., Bussieres, J. F., Langlois, E. and Lefebvre, M. (2009) Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J. Oncol. Pharm. Pract., 15, 53-61.
96. Hirst, M., Tse, S., Mills, D. G., Levin, L. and White, D. F. (1984) Occupational exposure to cyclophosphamide. Lancet, 1, 186-188. (Pubitemid 14221990)
97. Stellman, J. M., Aufiero, B. M. and Taub, R. N. (1984) Assessment of potential exposure to antineoplastic agents in the health care setting. Preven. Med., 13, 245-255. (Pubitemid 14042054)
98. Moller, P. (2006) The alkaline comet assay: towards validation in biomonitoring of DNA damaging exposures. Basic Clin. Pharmacol. Toxicol., 98, 336-345.
99. Angerer, J., Ewers, U. and Wilhelm, M. (2007) Human biomonitoring: state of the art. Int. J. Hyg. Environ. Health, 210, 201-228. (Pubitemid 46618114)
100. Valverde, M. and Rojas, E. (2009) Environmental and occupational biomonitoring using the Comet assay. Mutat. Res., 681, 93-109.